UK ABPI will encourage members to explore adaptive licensing with MHRA, EMA
This article was originally published in SRA
Executive Summary
The UK government has shown support for adaptive licensing as a key tool to promote innovation in the pharmaceutical industry. In fact, life science champions in the UK regard adaptive licensing as a "particularly important regulatory reform for small and medium sized enterprises, which could potentially transform the life cycle of small companies and provide earlier access"1.